In contrast, VHL alterations did not exceed 30% in the other renal subtypes showing either small or no mutation/deletion overlap in oncocytoma (n = 43) or papillary renal cell carcinoma (n = 58), respectively, and a strikingly low mutation rate of approx. 10% in chromophobe renal cell carcinomas. This evidence concerns the gene VHL and oncocytic adenoma.